近年来，嵌合抗原受体T（CAR-T）细胞疗法在难治性或复发性血液恶性肿瘤患者的治疗中取得了突破。然而，对于适合CAR-T细胞治疗的患者的识别仍需改进。CAR-T细胞治疗在血液恶性肿瘤中表现出优异的疗效；然而，从评估患者特征的角度来确定何时应用CAR-T细胞的观点仍存在争议。我们回顾了目前CAR-T细胞治疗最常见的血液恶性肿瘤的可行性和挑战，并根据疾病类型和类型对其进行了分类治疗优先，指导临床医生和研究人员进一步应用和研究 CAR-T 细胞。

In recent years, chimeric antigen receptor T (CAR-T) cell therapy has resulted in a breakthrough in the treatment of patients with refractory or relapsed hematological malignancies. However, the identification of patients suitable for CAR-T cell therapy needs to be improved.CAR-T cell therapy has demonstrated excellent efficacy in hematological malignancies; however, views on determining when to apply CAR-T cells in terms of the evaluation of patient characteristics remain controversial.We reviewed the current feasibility and challenges of CAR-T cell therapy in the most common hematological malignancies and classified them according to disease type and treatment priority, to guide clinicians and researchers in applying and investigating CAR-T cells further.